Lyell Immunopharma announced the completion of technology transfer for its LYL273 CAR T-cell product candidate to its LyFE Manufacturing Facility in Bothell, Washington, following FDA review. The company is continuing dosing of additional patients with the new manufacturing process in its Phase 1/2 trial for relapsed/refractory metastatic colorectal cancer to determine the recommended Phase 2 dose and optimize safety management. Additional clinical data and an End-of-Phase 1 meeting with the FDA are now expected in 2027. Lyell Immunopharma is a late-stage clinical company advancing next-generation CAR T-cell therapies for hematologic malignancies and solid tumors.

Lyell Immunopharma reported a net loss of $44.8 million for the quarter ended June 30, 2026, compared to $42.7 million in the prior year period. Research and development expenses increased by $4.7 million to $39.5 million due to heightened clinical trial activity. The company holds approximately $228.0 million in cash, cash equivalents, and marketable securities as of June 30, 2026, providing a runway into the third quarter of 2027. Clinically, updated safety data for ronde-cel showed no Grade ≥ 3 cytokine release syndrome events in over 100 patients, supporting potential outpatient administration. For LYL273, gastrointestinal prophylaxis reduced Grade ≥ 2 diarrhea or colitis rates from 55% to 10%, prompting an amendment of the U.S. Phase 1 trial to a Phase 1/2 design. Lyell Immunopharma is a late-stage clinical company advancing next-generation CAR T-cell therapies for hematologic malignancies and solid tumors.